Listing of Claims

The following listing of Claims will replace all prior versions and listings of Claims in the Application.

Claims

1-10 (Cancelled)

11. (Currently Amended) A pharmaceutical composition comprising a compound of formula (1a) ~~according to claim 14~~ :



(Ia)

wherein R^a is selected from halogen, hydroxy, (C_1-C_6)alkoxy, cyano, nitro, amino, hydroxycarbonyl,
C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl,
hydroxyC_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, perfluoro C_1-C_6 alkyl, perfluoroC_1-C_6 alkoxy,
C_1-C_6 alkylamino, di- C_1-C_6 alkylamino, aminoC_1-C_6 alkyl, C_1-C_6 alkylaminoC_1-C_6 alkyl, di-C_1-C_6 alkylaminoC_1-C_6 alkyl,
C_1-C_6acyl, C_1-C_6acyloxy, C_1-C_6acyloxyC_1-C_6 alkyl, C_1-C_6 acylamino,
C_1-C_6 alkylthiocarbonyl, C_1-C_6 alkylthioxo, C_1-C_6 alkoxycarbonyl,
C_1-C_6 alkylsulfonyl, C_1-C_6 alkylsulfonylamino,
aminosulfonyl, C_1-C_6 alkylaminosulfonyl, di-C_1-C_6 alkylaminosulfonyl,
3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl;

R^b is selected from hydrogen, halogen, hydroxy, (C_1-C_6)alkoxy cyano, nitro, amino, hydroxycarbonyl,
C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl,

C_1-C_6 alkoxy, hydroxyC_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, perfluoro C_1-C_6 alkyl, perfluoroC_1-C_6 alkoxy,
C_1-C_6 alkylamino, di- C_1-C_6 alkylamino, aminoC_1-C_6 alkyl, C_1-C_6 alkylaminoC_1-C_6 alkyl, di-C_1-C_6 alkylaminoC_1-C_6 alkyl,
C_1-C_6acyl, C_1-C_6acyloxy, C_1-C_6acyloxyC_1-C_6 alkyl, C_1-C_6 acylamino,
C_1-C_6 alkylthio, C_1-C_6 alkylthiocarbonyl, C_1-C_6 alkylthioxo, C_1-C_6 alkoxycarbonyl,
C_1-C_6 alkylsulfonyl, C_1-C_6 alkylsulfonylamino,
aminosulfonyl, C_1-C_6 alkylaminosulfonyl, di-C_1-C_6 alkylaminosulfonyl,
3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl;
or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents or carriers.

12. (Previously Presented) A combination comprising a compound of formula (Ia) according to claim 14, or a pharmaceutically acceptable salt thereof, and at least one other therapeutically active agent.

13. (Currently Amended) A combination according to claim 12, wherein the other therapeutically active agent is a PDEV inhibitor selected from sildenafil, vardenafil, tadalafil, 1-{6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3- d]pyrimidin-5-yl]-3-pyridylsulfonyl}-4-ethylpiperazine, 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one and 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one.

14. (Previously Presented) A compound of formula (Ia):



(Ia)

wherein R^a is selected from halogen, hydroxy, (C_1-C_6)alkoxy, cyano, nitro, amino, hydroxycarbonyl,
C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl,
hydroxyC_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, perfluoro C_1-C_6 alkyl, perfluoroC_1-C_6 alkoxy,
C_1-C_6 alkylamino, di- C_1-C_6 alkylamino, aminoC_1-C_6 alkyl, C_1-C_6 alkylaminoC_1-C_6 alkyl, di-C_1-C_6 alkylaminoC_1-C_6 alkyl,
C_1-C_6acyl, C_1-C_6acyloxy, C_1-C_6acyloxyC_1-C_6 alkyl, C_1-C_6 acylamino,
C_1-C_6 alkylthiocarbonyl, C_1-C_6 alkylthioxo, C_1-C_6 alkoxycarbonyl,
C_1-C_6 alkylsulfonyl, C_1-C_6 alkylsulfonylamino,
aminosulfonyl, C_1-C_6 alkylaminosulfonyl, di-C_1-C_6 alkylaminosulfonyl,
3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl;

R^b is selected from hydrogen, halogen, hydroxy, (C_1-C_6)alkoxy cyano, nitro, amino, hydroxycarbonyl,
C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl,
C_1-C_6 alkoxy, hydroxyC_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, perfluoro C_1-C_6 alkyl, perfluoroC_1-C_6 alkoxy,
C_1-C_6 alkylamino, di- C_1-C_6 alkylamino, aminoC_1-C_6 alkyl, C_1-C_6 alkylaminoC_1-C_6 alkyl, di-C_1-C_6 alkylaminoC_1-C_6 alkyl,
C_1-C_6acyl, C_1-C_6acyloxy, C_1-C_6acyloxyC_1-C_6 alkyl, C_1-C_6 acylamino,
C_1-C_6 alkylthio, C_1-C_6 alkylthiocarbonyl, C_1-C_6 alkylthioxo, C_1-C_6 alkoxycarbonyl,
C_1-C_6 alkylsulfonyl, C_1-C_6 alkylsulfonylamino,
aminosulfonyl, C_1-C_6 alkylaminosulfonyl, di-C_1-C_6 alkylaminosulfonyl,
3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl; or a pharmaceutically acceptable salt thereof.

15. (Withdrawn) A compound of formula (Ib):



(Ib)

wherein R^a is selected from halogen, hydroxy, cyano, nitro, amino, hydroxycarbonyl,
C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl,
hydroxyC_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, perfluoroC_1-C_6 alkoxy,
C_1-C_6 alkylamino, di- C_1-C_6 alkylamino, aminoC_1-C_6 alkyl, C_1-C_6 alkylaminoC_1-C_6 alkyl,
di-C_1-C_6 alkylaminoC_1-C_6 alkyl,
C_1-C_6acyl, C_1-C_6acyloxy, C_1-C_6acyloxyC_1-C_6 alkyl, C_1-C_6 acylamino,
C_1-C_6 alkylthio, C_1-C_6 alkylthiocarbonyl, C_1-C_6 alkylthioxo, C_1-C_6 alkoxycarbonyl,
C_1-C_6 alkylsulfonyl, C_1-C_6 alkylsulfonylamino,
aminosulfonyl, C_1-C_6 alkylaminosulfonyl, di-C_1-C_6 alkylaminosulfonyl,
3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl;

R^b is selected from hydrogen, halogen, hydroxy, (C_1-C_6)alkoxy cyano, nitro, amino, hydroxycarbonyl,
C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl,
C_1-C_6 alkoxy, hydroxyC_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, perfluoro C_1-C_6 alkyl,
perfluoroC_1-C_6 alkoxy,
C_1-C_6 alkylamino, di- C_1-C_6 alkylamino, aminoC_1-C_6 alkyl, C_1-C_6 alkylaminoC_1-C_6 alkyl,
di-C_1-C_6 alkylaminoC_1-C_6 alkyl,
C_1-C_6acyl, C_1-C_6acyloxy, C_1-C_6acyloxyC_1-C_6 alkyl, C_1-C_6 acylamino,
C_1-C_6 alkylthio, C_1-C_6 alkylthiocarbonyl, C_1-C_6 alkylthioxo, C_1-C_6 alkoxycarbonyl,
C_1-C_6 alkylsulfonyl, C_1-C_6 alkylsulfonylamino,
aminosulfonyl, C_1-C_6 alkylaminosulfonyl, di-C_1-C_6 alkylaminosulfonyl,
3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl;
or a pharmaceutically acceptable salt thereof.

16. (Withdrawn) A compound of formula (Ic):



(Ic)

wherein R^a and R^b are independently selected from hydrogen, halogen, hydroxy, (C_1-C_6)alkoxy, cyano, nitro, amino, hydroxycarbonyl, C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl, C_1-C_6 alkoxy, hydroxyC_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, perfluoro C_1-C_6 alkyl, perfluoroC_1-C_6 alkoxy, C_1-C_6 alkylamino, di- C_1-C_6 alkylamino, aminoC_1-C_6 alkyl, C_1-C_6 alkylaminoC_1-C_6 alkyl, di-C_1-C_6 alkylaminoC_1-C_6 alkyl, C_1-C_6acyl, C_1-C_6acyloxy, C_1-C_6acyloxyC_1-C_6 alkyl, C_1-C_6 acylamino, C_1-C_6 alkylthio, C_1-C_6 alkylthiocarbonyl, C_1-C_6 alkylthioxo, C_1-C_6 alkoxycarbonyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylsulfonylamino, aminosulfonyl, C_1-C_6 alkylaminosulfonyl, di-C_1-C_6 alkylaminosulfonyl, 3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl;
or a pharmaceutically acceptable salt thereof.

17. (Withdrawn, Currently Amended) A compound of formula (1a) according to claim ~~1~~ 14 which is:
(2*S*, 4*S*)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid;
Or a pharmaceutically acceptable salt thereof.

18. (Withdrawn) A compound of formula (1b) according to claim 15 which is selected from the group consisting of:
(2*S*,4*S*)-4-(3-Fluoro-benzyl)-pyrrolidine-2-carboxylic acid;
(2*S*,4*S*)-4-(2,3-Difluoro-benzyl)-pyrrolidine-2-carboxylic acid; and
(2*S*,4*S*)-4-(2,5-Difluoro-benzyl)-pyrrolidine-2-carboxylic acid; or a pharmaceutically acceptable salt thereof.

19. (Withdrawn) A compound of formula (1c) according to claim 16 which is selected from the group consisting of:
(2*S*,4*S*)-4-(3-Fluoro-phenoxymethyl)-pyrrolidine-2-carboxylic acid;
(2*S*,4*S*)-4-(3,6-Difluoro-phenoxymethyl)-pyrrolidine-2-carboxylic acid;
(2*S*,4*S*)-4-(2,3-Difluoro-phenoxymethyl)-pyrrolidine-2-carboxylic acid; and
(2*S*,4*S*)-4-(3-Methoxy- phenoxymethyl)-pyrrolidine-2-carboxylic acid; or a pharmaceutically acceptable salt thereof.

20. (Withdrawn) A pharmaceutical composition comprising a compound of formula (1b) according to claim 15, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents or carriers.

21. (Withdrawn) A pharmaceutical composition comprising a compound of formula (1b) according to claim 15, or a pharmaceutically acceptable salt thereof, and at least one other therapeutically active agent.

22. (Withdrawn) A combination according to claim 21, wherein the other therapeutically active agent is a PDEV inhibitor.

23. (Withdrawn) A pharmaceutical composition comprising a compound of formula (1c) according to claim 16, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents or carriers.

24. (Withdrawn) A pharmaceutical composition comprising a compound of formula (1c) according to claim 16, or a pharmaceutically acceptable salt thereof, and at least one other therapeutically active agent.

25. (Withdrawn) A combination according to claim 24, wherein the other therapeutically active agent is a PDEV inhibitor.

26. (Withdrawn) The compound (2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt thereof.